Alvimopan as Rescue in Post op Ileus

Phase 3

Terminated

Conditions: Ileus
Colorectal Surgery

Interventions: Drug: Alvimopan
Other: Control Group

Registration Number: NCT02742181

Lead Sponsor: Sharon Stein

Brief Summary: This will be a prospective randomized control trial with a total of 142 patients. Patients who undergo laparoscopic or open colorectal resection, small bowel resection, or ileostomy reversal with small bowel resection that subsequently develop postoperative ileus will be eligible for enrollment. If they meet inclusion/exclusion criteria, they will be randomized at the time of diagnosis of postoperative ileus to receive Entereg as rescue therapy or to receive conservative standard care.

Patients randomized to the Entereg group will be given 12mg of Entereg two times daily from the time of randomization until the return of bowel function or 5 days. Both groups will be treated with conservative standard care, including bowel rest, reduction in oral diet, and placement of nasogastric tube as clinically indicated.

All patients will follow a standard ERAS pathway after surgery, with early feeding and ambulation, along with opioid minimizing measures as is our standard postoperative protocol.

Primary outcome will be hospital length of stay. Secondary outcomes will include time to return of bowel function, 30-day morbidity/mortality, complications, reoperation and readmission.

Total number of patients: 142 Patients in each study group: 71

Detailed Description: At the time of diagnosis of postoperative ileus and after enrollment and randomization, all patients will be returned to NPO status. Nasogastric tubes (NGT) may be placed for gastric decompression at the discretion of the surgical team if clinically indicated. In the event that an NGT is placed, medications will be given orally or via the NGT, which will be clamped for 30 minutes after administration. Patients will continue on standard ERAS pathways with the exception of reduction of diet. Antiemetics will be given as clinically indicated; however, no prokinetic or promotility agents will be given as scheduled dosages.

Patients randomized to the study group will be given 12mg of Entereg orally twice a day, from the time of diagnosis of postoperative ileus to the time of return of bowel function or for 5 days.

Patients randomized to the control group receive standard postoperative care.

The patient and surgical team will be able to know which arm of the study the patient is in based on documentation in the medical record of the administration of Entereg.

Patients in both groups will remain NPO until the return of bowel function, defined as passage of stool, decrease in nasogastric tube output. At this point, the nasogastric tube will be removed and a trial of oral diet will be attempted per surgeon's discretion.

Standard discharge criteria will be applied to all patients, including:

* Passage of stool

* Ability to tolerate solid food and to drink comfortably

* Adequate oral analgesia

* Patient's willingness to be discharged.

Data to be collected The medical/surgical information below will be collected as part of this research study and is all information already available as part of the patients medical chart.

* Patient name, medical record number

* Past Medical History

* Past Surgical history

* Preoperative Medications (including steroids, anticoagulation, opioid use)

* Pre-operative Diagnosis

* Patient Demographics (age, gender, BMI, ASA score)

* Procedure performed

* Time of surgery

* Wound classification

* Estimated blood loss

* Intraoperative transfusion

* Intraoperative IV fluids given

* Conversion from laparoscopic to open procedure

* Stoma creation

* Time/day surgery to ileus

* Time from surgery to medication given

* Time from ileus diagnosis to medication given

* Was there return of bowel function (flatus or stool, solid or liquid, stoma output) prior to ileus

* Intra-abdominal infection/anastomotic leak

* Time/day of return of bowel function post ileus (flatus and stool- solid or liquid, and stoma function)

* Time/day of ability to tolerate oral diet (liquid and solid food)

* Nasogastric tube placement and daily output

* Duration of nasogastric tube

* Use and type of anti-emetics given

* Total number of Entereg doses given

* Post operative complications including reoperation

* Length of stay in hospital, defined as time from surgery to discharge

* 30-day readmissions

Study Completion Completion of participation in the study will be 30 days after the date of surgery. Any readmission up to 30 days post-operatively to the hospital as a direct result of their surgery will be followed. The patients will follow-up with the surgeon in the office in approximately 3-6 weeks, which is considered standard of care for all patients undergoing colorectal surgery and is not considered part of the research study. Any patient for whom follow-up documentation is missing or incomplete shall be contacted via telephone. The purpose of the call will be to simply determine return to function and outcome. Only a co-investigator shall contact the subject and will identify themselves at the beginning of the call. Any subject can reserve the right not to participate in the phone call interview; they would remain in the study.

Recruitment & Eligibility

Status: TERMINATED

Sex: All

Target Recruitment: 14

Inclusion Criteria

Subjects who have benign or malignant colonic or rectal disease that have undergone laparoscopic or open colorectal resection, small bowel resection or ileostomy reversal with small bowel resection and subsequently developed postoperative ileus, defined as:
- Return to NPO status after initial diet attempts, or
- Placement of nasogastric tube
Subjects who are 18 years of age and older
Subjects of either gender
Subjects who are willing and able to adhere to protocol requirements, agree to participate in the study program and provide written and informed consent.

Exclusion Criteria

Subjects who received Entereg preoperatively.
Subjects that have taken therapeutic doses of opioids for more than 7 days immediately prior to surgery.
Subjects with severe hepatic impairment.
Subjects with end-stage renal disease.
Subjects who are pregnant.
Subjects who were diagnosed with a complete small bowel obstruction preoperatively.
Subjects with a medical condition that may interfere with the use of the study medication Entereg.
Subjects who have a condition or general disability or infirmity that in the opinion of the investigator precludes further participation in the study

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Alvimopan group	Alvimopan	In addition to standard postoperative care, patients randomized to the study group will be given 12mg of alvimopan orally twice a day, from the time of diagnosis of postoperative ileus to the time of return of bowel function or for 5 days.
Control Group	Control Group	Patients randomized to the control group receive standard postoperative care which includes but is not limited to NPO status, IV fluid rehydration, and nasogastric decompression.

Primary Outcome Measures

Name	Time	Method
Hospital Length of Stay	up to 30 days	Date of surgery until discharge

Secondary Outcome Measures

Name	Time	Method
Time to Return of Bowel Function	30 days	Date ileus identified to time of passing flatus, stool and tolerating diet
Complications	30 days	All adverse events
Number of Readmissions	30 days	Any readmissions within 30 days of surgery
Number of Reoperations	30 days	Any reoperations within 30 days of surgery